Latest Asx News

Eagle Mountain Mining’s recent age-dating confirms Laramide-age latite dykes at its Silver Mountain Project, aligning it with world-class copper porphyry deposits in Arizona and enhancing its exploration prospects.

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.

EQ Resources announces a strategic leadership reshuffle, transitioning CEO Kevin MacNeill to CTO to sharpen operational focus and support ambitious growth plans across Australia and Spain.

Saturn Metals made significant progress on its Apollo Hill Gold Project during the December 2024 quarter, reporting strong drilling results and advancing its Pre-Feasibility Study despite a tragic on-site fatality. The company ended the quarter with a solid cash position of $9.5 million.

Peninsula Energy has resumed uranium production at its Lance Project in Wyoming, capturing 1,100 pounds of uranium in late December 2024, while securing key regulatory approvals to expand mining operations.

Latrobe Magnesium Limited has responded to an ASX price query, denying any undisclosed information that could explain the recent sharp drop in its share price and surge in trading volume.

Amcor plc and Berry Global Group, Inc. have entered into a definitive merger agreement for an all-stock transaction valued at approximately $9.9 billion. The combined entity aims to leverage significant synergies and enhanced market reach, pending shareholder and regulatory approvals.

Brazilian Critical Minerals has released an updated Mineral Resource Estimate for its Ema rare earth project in Brazil, defining a robust 350Mt starter zone at 778ppm TREO. This milestone underpins the imminent Scoping Study and signals promising economic potential for the project.

Basin Energy advances its Scandinavian uranium exploration with new land applications and awaits key sampling results, buoyed by Sweden's move to lift its uranium mining ban.

Telix Pharmaceuticals has exceeded its full-year 2024 revenue guidance, driven by strong sales of its prostate cancer diagnostic Illuccix® and strategic pipeline advancements.

The Australian Takeovers Panel has declared unacceptable circumstances in Alara Resources Limited's recent rights issue, citing inadequate disclosure and potential control issues involving Al Tasnim Infrastructure LLC. The company faces a costs order and must reassess its fundraising approach.

Foresta Group Holdings secures a significant regulatory boost as its Kawerau renewable energy project is included in New Zealand’s Fast-Track Approvals Act 2024, expediting the path to construction and operation.